1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended February 28, 1998
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________________ to _______________________
Commission File No. 0-11488
PENFORD CORPORATION
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Washington 91-1221360
- --------------------------------------------------------------------------------
(State of Incorporation) (I.R.S. Employer
Identification No.)
777-108th Avenue N.E., Suite 2390, Bellevue, WA 98004-5193
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (425) 462-6000
Indicate by a check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
----- -----
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of March 27, 1998.
Class Outstanding
----- -----------
Common stock, par value $1.00 7,300,661
2
PENFORD CORPORATION AND SUBSIDIARIES
INDEX
Page No.
--------
PART I - FINANCIAL INFORMATION
Item 1 - Financial Statements
Condensed Consolidated Balance Sheets
February 28, 1998 and August 31, 1997 3
Condensed Consolidated Statements of Income
Three and Six Months Ended February 28, 1998
and February 28, 1997 4
Condensed Consolidated Statements of Cash Flow
Six Months Ended February 28, 1998 and
February 28, 1997 5
Notes to Condensed Consolidated Financial Statements 6-8
Item 2 - Management's Discussion and Analysis of
Financial Condition and Results of Operations 9-12
Item 3 - Quantitative and Qualitative Disclosures 12
About Market Risk
PART II - OTHER INFORMATION
Item 1 - Legal Proceedings 13
Item 2 - Changes in Securities 13
Item 3 - Defaults Upon Senior Securities 13
Item 4 - Submission of Matters to a Vote of Security Holders 13-14
Item 5 - Other Information 14
Item 6 - Exhibits and Reports on Form 8-K 14-16
SIGNATURES 17
2
3
PART I - FINANCIAL INFORMATION
Item 1 Financial Statements
PENFORD CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in Thousands)
February 28, 1998 August 31, 1997
----------------- ---------------
ASSETS
Current assets:
Cash and cash equivalents $ 176
Trade accounts receivable $ 26,788 27,181
Inventories:
Raw materials and other 7,403 6,624
Work in progress 924 886
Finished goods 13,889 14,325
--------- ---------
22,216 21,835
Prepaid expenses and other 7,933 5,179
--------- ---------
Total current assets 56,937 54,371
Net property, plant and equipment 131,823 130,374
Deferred income taxes 11,020 11,007
Restricted cash value of life insurance 13,765 12,691
Other assets 7,689 7,486
--------- ---------
Total assets $ 221,234 $ 215,929
========= =========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Bank overdraft, net $ 1,869
Accounts payable 9,259 $ 10,089
Accrued liabilities 8,748 8,157
Current portion of long-term debt 13,697 5,955
--------- ---------
Total current liabilities 33,573 24,201
Long-term debt 54,223 61,791
Other postretirement benefits 10,632 10,294
Deferred income taxes 22,251 22,136
Other liabilities 8,853 8,406
Shareholders' equity:
Common stock 9,100 9,093
Additional paid-in capital 19,238 18,466
Retained earnings 94,637 93,854
Treasury stock (30,086) (30,604)
Note receivable from Savings and
Stock Ownership Plan (497) (639)
Cumulative translation adjustment (690) (1,069)
--------- ---------
Total shareholders' equity 91,702 89,101
--------- ---------
Total liabilities and shareholders' equity $ 221,234 $ 215,929
========= =========
See accompanying notes to condensed consolidated financial statements.
3
4
PENFORD CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Dollars in thousands except per share data)
Three Months Six Months
Ended February 28 Ended February 28
------------------------------- -------------------------------
1998 1997 1998 1997
----------- ----------- ----------- -----------
Sales $ 47,490 $ 48,327 $ 96,013 $ 97,637
Cost of sales 34,780 36,129 70,414 74,629
----------- ----------- ----------- -----------
Gross margin 12,710 12,198 25,599 23,008
Operating expenses 9,661 9,124 20,376 17,716
----------- ----------- ----------- -----------
Income from operations 3,049 3,074 5,223 5,292
Other income 1,200
Interest expense, net (1,470) (1,279) (2,879) (2,576)
----------- ----------- ----------- -----------
Income before income taxes 1,579 1,795 2,344 3,916
Income taxes 564 539 832 1,253
----------- ----------- ----------- -----------
Net income $ 1,015 $ 1,256 $ 1,512 $ 2,663
=========== =========== =========== ===========
Weighted average common shares 7,292,632 6,883,499 7,280,334 6,867,378
Weighted average common shares
assuming dilution 7,519,637 7,013,463 7,525,064 7,003,261
Earnings per common share $ 0.14 $ 0.18 $ 0.21 $ 0.39
=========== =========== =========== ===========
Earnings per common share,
assuming dilution $ 0.13 $ 0.18 $ 0.20 $ 0.38
=========== =========== =========== ===========
Dividends declared per common share $ 0.05 $ 0.05 $ 0.10 $ 0.10
=========== =========== =========== ===========
See accompanying notes to condensed consolidated financial statements.
4
5
PENFORD CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW
(Dollars in Thousands)
Six Months
Ended February 28
-------------------------
1998 1997
-------- --------
Operating Activities:
Net income $ 1,512 $ 2,663
Adjustments to reconcile net income to net cash
from operating activities:
Depreciation 6,542 5,803
Deferred income taxes 102 488
Change in operating assets and liabilities:
Trade receivables 393 (820)
Inventories (381) 1,215
Accounts payable, prepaids and other (1,708) (696)
-------- --------
Net cash from operating activities 6,460 8,653
Investing Activities:
Additions to property, plant and equipment (7,874) (13,563)
Other 928 512
-------- --------
Net cash used by investing activities (6,946) (13,051)
Financing Activities:
Proceeds from unsecured line of credit 48,330 42,655
Payments on unsecured line of credit (47,620) (38,915)
Proceeds from long-term debt 5,000 5,000
Payments on long-term debt (5,536) (3,492)
Exercise of stock options 154 441
Purchase of life insurance for officers' benefit plans (1,158) (1,158)
Payment of dividends (729) (684)
-------- --------
Net cash from (used by) financing activities (1,559) 3,847
-------- --------
Net decrease in cash and cash equivalents (2,045) (551)
Cash and cash equivalents (bank overdraft) at
beginning of period 176 (847)
-------- --------
Net bank overdraft at end of period ($ 1,869) ($ 1,398)
======== ========
See accompanying notes to condensed consolidated financial statements.
5
6
PENFORD CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements
have been prepared in accordance with generally accepted accounting
principles for interim financial information and with the instructions
to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not
include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements. In the
opinion of management, all adjustments (consisting of normal recurring
accruals) considered necessary for a fair presentation for the interim
periods presented have been included. Operating results for the three
and six month periods ended February 28, 1998 are not necessarily
indicative of the results that may be expected for the year ending
August 31, 1998. For further information, refer to the consolidated
financial statements and footnotes thereto included in Penford
Corporation's ("Penford" or the "Company") annual report on Form 10-K
for the fiscal year ended August 31, 1997.
Certain prior year amounts have been reclassified to conform with
current year presentation. These reclassifications had no effect on
previously reported results of operations.
2. INCOME TAXES
The effective tax rate for the quarter and for the six months ended
February 28, 1998 was 35.7% and 35.5%, respectively. The effective rate
is higher than the federal statutory rate of 34.0% due primarily to the
effects of state income taxes. The effective tax rate for the quarter
and six months ended February 28, 1997 was 30.0% and 32.0%,
respectively. The effective rate was lower than the federal statutory
rate in these periods due primarily to the effects of income tax refunds
received in the prior year.
3. EARNINGS PER COMMON SHARE
During the second quarter of fiscal 1998, the Company adopted Statement
of Financial Accounting Standards (SFAS) No. 128, "Earnings per Share."
Statement No. 128 replaced the previously reported primary and fully
diluted earnings per share with basic and diluted earnings per share.
Basic earnings per share reflects only the weighted average common
shares outstanding. Diluted earnings per share reflects weighted average
common shares outstanding and the effect of any dilutive common stock
equivalent shares. All earnings per share amounts have been presented
and where necessary, have been restated to conform with the requirements
of SFAS No. 128.
6
7
The following table presents the computation of basic and diluted
earnings per share under SFAS No. 128 (dollars in thousands, except per
share data):
Three Months Ended Six Months Ended
February 28 February 28
----------- -----------
1998 1997 1998 1997
---------- ---------- ---------- ----------
Net income $ 1,015 $ 1,256 $ 1,512 $ 2,663
========== ========== ========== ==========
Weighted average common
shares outstanding 7,292,632 6,883,499 7,280,334 6,867,378
Net effect of dilutive
stock options 227,005 129,964 244,730 135,883
---------- ---------- ---------- ----------
Weighted average common shares
outstanding assuming dilution 7,519,637 7,013,463 7,525,064 7,003,261
========== ========== ========== ==========
Earnings per common share $ 0.14 $ 0.18 $ 0.21 $ 0.39
========== ========== ========== ==========
Earnings per common share,
assuming dilution $ 0.13 $ 0.18 $ 0.20 $ 0.38
========== ========== ========== ==========
4. PLANNED INITIAL PUBLIC OFFERING AND SPIN-OFF OF PENWEST PHARMACEUTICALS CO.
During the first quarter of fiscal 1998, the Company announced a two stage
plan designed to foster the growth potential of its pharmaceuticals
business, and separately, its specialty paper chemicals and food ingredients
businesses. Under the first stage of the plan, the Company's Penwest
Pharmaceuticals Co. (PPC) subsidiary would sell up to 20% of its common
stock through an initial public offering. Under the second stage of the
plan, Penford would effect a tax-free spin-off to its shareholders of the
remaining ownership of PPC shares contingent upon satisfying certain
conditions. The spin-off was anticipated to occur in the second calendar
quarter of 1998.
On October 21, 1997, PPC filed a registration statement with the Securities
and Exchange Commission for an initial public offering of 2,500,000 shares
of common stock (approximately 15% of its outstanding common stock). The
estimated initial public offering price set forth in the registration
statement was $10.00 to $12.00 per share with an option for the underwriters
to purchase up to 375,000 additional shares for the purpose of covering
over-allotments, if any.
On December 18, 1997, Penford postponed the initial public offering of PPC
due to market conditions for new issues in general as well as for health
care and technology stocks in particular. The Company intends to go forward
with the offering as soon as practicable after market conditions improve.
This postponement will cause the planned spin-off to be delayed beyond the
second calendar quarter of 1998. The Company has deferred certain costs
incurred in connection with the plan which totaled approximately $3.2
million as of February 28, 1998. It is anticipated that certain of these
costs, including additional costs to be incurred, will be charged to expense
in the third quarter.
7
8
PPC will retain the net proceeds from the planned initial public offering.
Penford will forgive intercompany advances as of the closing of the
offering. As of February 28, 1998, the intercompany balance approximated
$40.0 million. Had the plan been effected as of February 28, 1998,
consolidated assets and shareholders' equity of Penford would have reflected
a reduction of approximately $35.0 to $40.0 million, representing the net
effects of the proposed distribution.
Summarized quarterly financial data of PPC as of February 28, 1998 and for
the three and six months then ended follows (in 000's):
Three Months Six Months
Ended February 28 Ended February 28
--------------------- ---------------------
1998 1997 1998 1997
---- ---- ---- ----
Sales $ 6,804 $ 6,478 $ 13,547 $ 12,628
Pre-tax loss (1,847) (888) (4,292) (1,837)
Identifiable assets as of
February 28 $ 39,284 $ 36,110
8
9
Item 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
RESULTS OF OPERATIONS
Net income for the quarter ended February 28, 1998 was $1.0 million, or $0.13
per share assuming dilution, compared to net income of $1.3 million, or $0.18
per share assuming dilution, for the corresponding period a year ago. Net income
for the six months ended February 28, 1998 was $1.5 million, or $0.20 per share
assuming dilution, compared to $2.7 million, or $0.38 per share in the
corresponding period in fiscal 1997. The first six months of fiscal 1997
included other income of $1.2 million ($800,000 after tax), or $0.11 per share,
from a gain on the sale of Southern California air emission credits.
Penford's specialty paper chemicals and food ingredients businesses earned
income before taxes of $3.4 million in the second quarter
compared to $2.7 million the same quarter in the prior year. Penwest
Pharmaceuticals Co. incurred a pre-tax loss in the second quarter of $1.8
million compared to a loss of $888,000 in the same quarter in the prior year.
The Company, excluding PPC, earned income before taxes of $6.6 million and $5.8
million in the first six months of fiscal 1998 and 1997, respectively.
Corresponding losses of PPC for the six month periods were $4.3 million and $1.8
million in fiscal 1998 and 1997, respectively.
Total Company sales decreased in the second quarter and first six months of
fiscal 1998 to $47.5 million and $96.0 million, respectively, both representing
decreases of 1.7% from the corresponding periods in the prior year. The change
in sales was primarily due to the effects in the prior year of record high corn
costs which are reflected in the pricing of Penford's paper chemical products.
Corn prices have moderated and returned to historical levels in the current
fiscal year. Fiscal 1998 sales volume increases in the pharmaceuticals and food
ingredients businesses offset a portion of the decrease resulting from lower
prices.
Gross margin in the second quarter improved to 26.8% from 25.2 % in the
corresponding quarter a year earlier resulting primarily from lower corn prices
and operational efficiency initiatives. Increased sales volumes of high,
value-added specialty food grade starches and starch copolymers also contributed
to the margin improvement. Gross margin for the six months ended February 28,
1998 increased to 26.7% from 23.8% in the same period last year, as a result of
higher sales volumes of Penford paper chemical products, as well as the factors
noted above.
Operating expenses for the second quarter grew by $537,000, or 5.9%, compared to
the prior year period. For the six months ended February 28, 1998, operating
expenses increased $2.7 million, or 15.0%. The increase in the second quarter is
attributed primarily to higher research and development expenses related to
PPC's controlled release drug delivery technology. The year-to-date increase in
operating expense is primarily due to higher costs for the pharmaceuticals
operations including increased research and development costs and expenses
associated with building the infrastructure to support its anticipated growth as
well as increased sales and marketing efforts principally related to Penford
Products Co.
Net interest expense for the second quarter and first half of fiscal 1998 were
$1.5 million and $2.9 million, respectively, compared to $1.3 million and $2.6
million in the corresponding
9
10
periods a year ago. The increases reflect higher capitalized interest in the
prior year on several large projects in Cedar Rapids, Iowa and Richland,
Washington.
The effective tax rate for the second quarter and first half of fiscal 1998 was
35.7% and 35.5%, respectively, compared to 30.0% and 32.0% in the corresponding
periods a year ago. The increase in the effective tax rate in fiscal 1998 is due
to tax refunds received in the previous year and the effects of higher state
income taxes in fiscal 1998.
LIQUIDITY
At February 28, 1998, Penford had working capital of $23.4 million, an unsecured
credit agreement of $35.0 million under which there was $25.3 million
outstanding, and several uncommitted lines of credit aggregating $15.0 million
under which there was $6.7 million outstanding. The Company used operating cash
flow and debt to finance capital expenditures during the second quarter and
first six months of fiscal 1998.
Cash flow from operations for the six months ended February 28, 1998 was $6.5
million compared to $8.7 million in the corresponding period of the prior year.
The change in operating cash flow is due to the effects of unusually high corn
costs on the components of working capital in the prior year and lower net
income in the current year.
The Company paid a $0.05 per share dividend on December 5, 1997 and March 6,
1998.
CAPITAL RESOURCES
Additions to property, plant and equipment during the six months ended February
28, 1998 were $7.9 million. Second quarter additions of $4.0 million were
primarily for various improvements to the Penford Products Co. manufacturing
facility in Cedar Rapids, Iowa. Capital expenditures for the Company's specialty
paper chemicals and food ingredients businesses for the remainder of fiscal 1998
are expected to be consistent with the first half of the year.
Commencement of constructing laboratory and manufacturing facilities for PPC in
Patterson, New York has been postponed pending completion of the PPC initial
public offering. The project has an estimated total cost of approximately $15.0
million.
PLANNED INITIAL PUBLIC OFFERING AND SPIN-OFF OF PENWEST PHARMACEUTICALS CO.
During the first quarter of fiscal 1998, the Company announced a two stage plan
designed to foster the growth potential of its pharmaceuticals business, and
separately, its specialty paper chemicals and food ingredients businesses. Under
the first stage of the plan, the Company's Penwest Pharmaceuticals Co. (PPC)
subsidiary would sell up to 20% of its common stock through an initial public
offering. Under the second stage of the plan, Penford would effect a tax-free
spin-off to its shareholders of the remaining ownership of PPC shares contingent
upon satisfying certain conditions. The spin-off was anticipated to occur in the
second calendar quarter of 1998.
10
11
On October 21, 1997, PPC filed a registration statement with the Securities and
Exchange Commission for an initial public offering of 2,500,000 shares of common
stock (approximately 15% of its outstanding common stock). The estimated initial
public offering price set forth in the registration statement was $10.00 to
$12.00 per share with an option for underwriters to purchase up to 375,000
additional shares for the purpose of covering over-allotments, if any.
On December 18, 1997, Penford postponed the initial public offering of PPC due
to market conditions for new issues in general as well as for health care and
technology stocks in particular. The Company intends to go forward with the
offering as soon as practicable after market conditions improve. This
postponement will cause the planned spin-off to be delayed beyond the second
calendar quarter of 1998. The Company has deferred certain costs incurred in
connection with the plan which totaled approximately $3.2 million as of February
28, 1998. It is anticipated that certain of these costs, including additional
costs to be incurred, will be charged to expense in the third quarter.
YEAR 2000
The Company has undergone a review of its information systems, including
consideration of issues associated with the Year 2000. In connection with the
review, and as part of the Company's ongoing capital program, a series of
technology related expenditures are planned. Management believes the
expenditures, which are currently being implemented, will among other things,
satisfy the significant Year 2000 issues. Other Year 2000 expenditures are not
expected to be material.
FORWARD-LOOKING STATEMENTS
The above discussion contains forward-looking statements concerning the
completion of the proposed public offering and spin-off of Penwest
Pharmaceuticals Co., estimated capital expenditures, and the anticipated results
of the Company. There are a variety of factors which could cause actual events
to differ materially from those projected in the forward-looking statements,
including without limitation: (i) the risk that the public offering or the
spin-off may not be completed as the result of future developments in Penford
Corporation's or Penwest Pharmaceuticals Co.'s business or conditions in the
securities markets, failure to obtain necessary government rulings or approvals
or third party consents or agreements or other developments; and (ii) the risk
that results may be effected by construction delays, cost overruns, technical
difficulties, nonperformance by contractors or changes in capital improvement
project requirements or specifications; technical difficulties or cost overruns
in the Company's Year 2000 compliance program; competition; the possibility of
interruption of business activities due to accidents, strikes, weather or other
factors; product development risk; patents and intellectual property matters
(including patent infringement litigation, including the patent infringement
suit brought by Bayer AG and Pfizer Inc. against Mylan Laboratories Inc. as
described in the Company's Form 10-K for the fiscal year ended August 31, 1997
on file with the Securities and Exchange Commission); dependence on
collaborators; regulatory and manufacturing issues including the difficulties of
obtaining FDA or other regulatory approvals; changes in raw material prices;
changes in general economic conditions or developments with respect to specific
industries or customers affecting demand for the Company's products; or other
unforeseen developments in the industries in which the Company operates.
Accordingly, there can be no assurance that the public offering or spin-off will
be completed, or that future activities or results will be as anticipated.
11
12
The registration statement filed by PPC with the Securities and Exchange
Commission has not yet become effective. The securities may not be sold nor may
offers to buy be accepted prior to the time the registration statement becomes
effective. The discussion included herein shall not constitute an offer to sell
or a solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction, in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Additional information which could affect the Company's financial results is
included in the Company's 1997 Annual Report to Shareholders and its Form 10-K
for the fiscal year ended August 31, 1997 on file with the Securities and
Exchange Commission. Penford assumes no obligation to update any forward-looking
statements should circumstances change.
Item 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK
Not applicable
12
13
PART II - OTHER INFORMATION
Item 1 Legal Proceedings
The registrant is unaware of any material developments in the legal
proceedings referred to in the Registrant's Report on Form 10-K for
the year ended August 31, 1997.
In November, 1997, the Company was notified by the Idaho Falls
Police Department that a nearby resident had complained about health
problems allegedly caused by starch emissions from the Company's
Idaho Falls facility. Subsequently, the Idaho Department of
Environmental Quality contacted the Company with regard to possible
violations of the Company's air quality permit limits. In December,
1997, a group of nearby residents filed a Notice of Intent to Bring
Suit with the Idaho Department of Environmental Quality and the U.S.
Environmental Protection Agency pursuant to the Clean Air Act, the
Comprehensive Environmental Response, Compensation and Liability
Act, and the Emergency Planning and Community Right-to-Know Act. The
Company is investigating these issues; however, the Company is
unable at this time to determine whether any claim or action will be
commenced or to estimate the Company's potential exposure, if any.
Item 2 Changes in Securities
Not applicable
Item 3 Defaults Upon Senior Securities
Not applicable
Item 4 Submission of Matters to a Vote of Security Holders
(a) The annual meeting of shareholders of Penford Corporation was held on
January 27, 1998.
(b) The following directors were elected to serve a term of three years:
Tod R. Hamachek and Sally G. Narodick. The board is comprised of
those elected this year and the following directors completing their
terms: Richard E. Engebrecht, Paul E. Freiman, Paul H. Hatfield,
William G. Parzybok, Jr., N. Stewart Rogers, and William K. Street.
(c) The following matters were voted upon at the meeting:
1. For the election of directors:
% of % of
For Voted Withheld Voted
--- ----- -------- -----
Tod R. Hamachek 6,284,705 99.82% 11,055 0.18%
Sally G. Narodick 6,282,347 99.79% 13,413 0.21%
13
14
2. Ratification of selection of Ernst & Young LLP as independent
auditors of the Company:
Broker
For Against Abstain Non-Vote
--------- --------- --------- ---------
6,269,619 7,546 18,595 0
(d) Not applicable
Item 5 Other Information
Not applicable
Item 6 Exhibits and Reports on Form 8-K.
(a) Exhibits:
(3.1) Restated Articles of Incorporation of Registrant (filed as
an Exhibit to Registrant's Form 10-K for fiscal year ended
August 31, 1995)
(3.2) Articles of Amendment to Restated Articles of Incorporation
of Registrant (filed as an exhibit to Registrant's Form 10-K
for fiscal year ended August 31, 1997)
(3.3) Bylaws of Registrant as amended and restated as of October
20, 1997 (filed as an exhibit to Registrant's Form 10-K for
fiscal year ended August 31, 1997)
(4.1) Amended and Restated Rights Agreement dated as of April 30,
1997 (filed as an Exhibit to Registrant's Amendment to
Registration Statement on Form 8-A/A dated May 5, 1997)
(10.1) Senior Note Agreement among Penford Corporation as Borrower
and Mutual of Omaha and Affiliates as lenders, dated
November 1, 1992 (filed as an Exhibit to Registrant's Form
10-Q for the quarter ended February 28, 1993)
(10.2) Loan Agreement among Penford Corporation as Borrower and
Seattle-First National Bank as Lender, dated December 1,
1989 (Registrant agrees to furnish a copy of this instrument
to the Commission on request)
(10.3) Penford Corporation Supplemental Executive Retirement Plan,
dated March 19, 1990 (filed as an Exhibit to Registrant's
Form 10-K for the fiscal year ended August 31, 1991)
(10.4) Penford Corporation Supplemental Survivor Benefit Plan,
dated January 15, 1991 (filed as an Exhibit to Registrant's
Form 10-K for the fiscal year ended August 31, 1991)
14
15
(10.5) Penford Corporation Deferred Compensation Plan, dated
January 15, 1991 (filed as an Exhibit to Registrant's Form
10-K for the fiscal year ended August 31, 1991)
(10.6) Change of Control Agreements with Messrs. Hamachek, Cook,
Widmaier, Talley, Horn, Rydzewski and Belsheim (a
representative copy of these agreements is filed as an
exhibit to Registrant's Form 10-K for the fiscal year ended
August 31, 1995)
(10.7) Penford Corporation 1993 Non-Employee Director Restricted
Stock Plan (filed as an Exhibit to Registrant's Form 10-Q
for the quarter ended November 30, 1993)
(10.8) Note Agreement dated as of October 1, 1994 among Penford
Corporation, Principal Mutual Life Insurance Company and TMG
Life Insurance Company (filed as an Exhibit to Registrant's
Form 10-Q for the quarter ended February 28, 1995)
(10.9) Penford Corporation 1994 Stock Option Plan as amended and
restated as of January 21, 1997 (filed on Form S-8 dated
March 17, 1997)
(10.10) Credit Agreement dated as of December 22, 1995 among Penford
Corporation, and its subsidiaries, Bank of America National
Trust and Savings Association, ABN-AMRO Bank, N.V., The Bank
of Nova Scotia, and Seattle-First National Bank (filed as an
exhibit to Registrant's Form 10-Q for the quarter ended
February 29, 1996)
(10.11) Amendment to Credit Agreement dated as of May 7, 1997 among
Penford Corporation and its subsidiaries, Bank of America
National Trust and Savings Association, ABN-AMRO Bank N.V.,
the Bank of Nova Scotia and Seattle-First National Bank
(filed as an exhibit to the Registrant's Form 10-Q for the
quarter ended May 31, 1997)
(10.12) Second Amendment to Credit Agreement dated as of November
28, 1997 among Penford Corporation and its subsidiaries,
Bank of America National Trust and Savings Association,
ABN-AMRO Bank, N.V., The Bank of Nova Scotia, and
Seattle-First National Bank (filed as an exhibit to the
Registrant's Form 10-Q for the quarter ended November 30,
1997)
(10.13) Penford Corporation Stock Option Plan for Non-Employee
Directors (filed as an exhibit to the Registrant's Form 10-Q
for the quarter ended May 31, 1996)
(10.14) Separation Agreement dated as of November 10, 1997 between
Registrant and Penwest Pharmaceuticals Co. (filed as an
exhibit to Registrant's Form 10-K for fiscal year ended
August 31, 1997)
27 Financial Data Schedules
15
16
(b) A Form 8-K was filed on December 18, 1997 reporting under Item 5
Registrant's postponement of the initial public offering of Penwest
Pharmaceuticals Co. Filed as an exhibit was a copy of a press release dated
December 18, 1997 relating to such postponement.
16
17
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Penford Corporation
------------------------------------
(Registrant)
April 3, 1998 /s/Tod R. Hamachek
- ------------- ------------------------------------
Date Tod R. Hamachek
President and
Chief Executive Officer (Principal
Executive Officer)
April 3, 1998 /s/Jeffrey T. Cook
- ------------- ------------------------------------
Date Jeffrey T. Cook
Vice President, Finance and
Chief Financial Officer (Principal
Financial Officer)
17